A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis
Recruiting now
Conditions studied: Atopic Dermatitis, Eczema
In brief
The main purpose of this study is to evaluate the impact of lebrikizumab treatment on the overall well-being of adult participants with moderate-to-severe AD in real-world clinical practice settings across Europe, as measured using validated 5-item World Health Organization Well-being Index (WHO-5) and to investigate effectiveness and safety of lebrikizumab, treatment satisfaction, and long-term effect of lebrikizumab treatment on participants in terms of disease symptomatology/control, fatigue, work impairment, patient's relationship with their skin, and overall QOL among adult participants.
Key facts
- Study ID
- NCT06815380
- Run by
- Almirall, S.A.
- People needed
- 1000
- Starts
- 2025-01-23
- Expected to finish
- 2029-03-01
- Last updated by the study team
- 2025-02-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult (greater than or equal to [>=] 18 years) male or female participants with diagnosis of moderate-to-severe Atopic dermatitis.
- Adult participants prescribed lebrikizumab as part of routine/usual care to manage their moderate-to severe Atopic dermatitis.
- Willingness and ability to participate in the study; participants must give their written consent to participate.
You may not qualify if…
- Hypersensitivity to the active substances or to any of the excipients of lebrikizumab (Ebglyss®).
- Participants with pre-existing helminth infections. These participants should be treated for helminth infection before starting lebrikizumab therapy.
- Concomitant use of live and live attenuated vaccines.
- Pregnant women, except when the potential benefit justifies the potential risk.
- Participants included in a clinical trial at baseline or at any time during the planned study period.
- Participants unable to comply with the requirements of the study or who, in the opinion of the study physician, should not participate in the study.
- Participants for whom medical chart is inaccessible to physicians to complete baseline data collection.
Where it is running
- Aarhus University Hospital — Aarhus, Denmark, Denmark (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.